Germany’s BioNTech SE signed a preliminary deal to set up a facility to produce cancer-related drugs and vaccines in Jerusalem, Israel’s Finance Ministry said on Tuesday.

MISSING PORCUPINE THAT DISAPPEARED FROM GERMAN ZOO FINDS ITS WAY BACK HOME

Under the memorandum of understanding, BioNTech will develop the drugs and vaccines using mRNA technology in the Har Hotzvim technology park. It will also set up a research centre at the Weizmann Institute in central Israel.